Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...

The biotech had tested the oral asset, dubbed VK2735, at doses ranging from 2.5 mg up to 100 mg. Viking already revealed back in March that 25% of the eight patients who received 20-mg doses saw their ...

Viking Therapeutics' highly anticipated weight-loss pill topped Wall Street's expectations — and a rival pill from Novo ...

Viking Therapeutics (VKTX) released new clinical trial data on Sunday for its experimental weight-loss drugs, which include a highly anticipated oral pill.

Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...

Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight ...

The company is expected to offer data on the higher dosing arms of 60, 80 and 100 milligrams at Obesity Week, which is organized by the Obesity Society and takes place Nov. 3-6 in San Antonio, Texas.

The drug, called amycretin and codenamed NN9487 ... patients out of a total planned enrolment of 144. After 12 weeks, weight loss with the drug was 13% of body weight, compared to 1% with placebo ...

Novo Nordisk and Eli Lilly still have first-mover advantage, but Roche, Pfizer and others all have similar products in the ...

The new pill, amycretin, mimics the weight-loss capabilities of Ozempic but is delivered in a pill rather than an injection.